FWFang Wang

Fang Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Fang Wang has a total of 119 co-authors. Here are the top co-authors by number of shared publications:

  • Changxiang Lai

    Department of Liver Diseases, National Clinical Research Center for Infectious Disease, Shenzhen Third People’s Hospital, Shenzhen, People’s Republic of China

    4 shared publications
  • Qiyuan Tang

    Department of Liver Diseases, National Clinical Research Center for Infectious Disease, Shenzhen Third People’s Hospital, Shenzhen, People’s Republic of China

    3 shared publications
  • Ruikun Chen

    Department of Liver Diseases, The Third People’s Hospital of Shenzhen, National Clinical Research Center for Infectious Disease, the Second Affiliated Hospital of Southern University of Science and Technology, Shenzhen, Guangdong, China

    2 shared publications
  • Wenjie Xian

    Department of Liver Diseases, The Third People’s Hospital of Shenzhen, National Clinical Research Center for Infectious Disease, the Second Affiliated Hospital of Southern University of Science and Technology, Shenzhen, Guangdong, China

    2 shared publications
  • Xuan Li

    Department of Liver Diseases, The Third People’s Hospital of Shenzhen, National Clinical Research Center for Infectious Disease, the Second Affiliated Hospital of Southern University of Science and Technology, Shenzhen, Guangdong, China

    2 shared publications
  • Zheng Zhang

    Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People’s Hospital, Shenzhen, China

    2 shared publications

Latest Publications

  • Open Access

    High HBsAg clearance rate and viral dynamics in HBeAg-positive, ALT-normal children and adolescents with chronic HBV infection: results from the prospective sprout project

    by Xin Wang, Changxiang Lai, Ruiling Li, Jia Lei, Yuyin Xie, Zhiyu Li, Qiyuan Tang, Qing He, Hongfei Zhang, Zheng Zhang, et al.

    Hepatitis B e antigen (HBeAg)-positive chronic hepatitis B virus (HBV) infection in children and adolescents with normal alanine aminotransferase (ALT) levels constitutes a substantial population in China, yet the optimal timing for antiviral therapy remains unclear. This prospective, real-world study, conducted as the primary center of the Sprout Project, evaluated the hepatitis B surface antigen (HBsAg) loss rate and viral-immune dynamics of pegylated interferon α (PEG-IFN-α) treatment in 85 chronic HBV patients aged 3-18 years over a 24-month period. A total of 27 HBeAg-positive, ALT-normal patients were selected for analysis. Patients were treated with a combination of PEG-IFN-α and entecavir. After 24 months, the overall HBsAg loss rate was 48.15%, with 47.37% in the immune-tolerant phase and 50% in the gray zone phase. Among those who cleared HBsAg, 84.62% had ALT elevation prior to anti-HBsAg antibody (HBsAb) seroconversion, which occurred 28 to 400 days before HBsAg loss. While HBsAg and HBV DNA were cleared by 24 months in the HBsAg loss group, 23.08% of children remained HBeAg-positive. Notably, 61.54% developed detectable HBsAb prior to HBsAg loss. Children aged 3 - 7 years had significantly higher clearance rates than those aged 8 - 18 years. These findings support the effectiveness of PEG-IFN-α combined with nucleos(t)ide analogs in achieving high HBsAg loss rates in young, HBeAg-positive, ALT-normal chronic HBV children and adolescents, with immune activation potentially preceding ALT elevation, and offers valuable insights into the viral-immune dynamics during treatment, highlighting the potential of antiviral therapy in this population.


  • Open Access

    Carvedilol to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by liver stiffness: study protocol for a randomied, double-blind, placebo-controlled, multicentre trial in China

    by Chuan Liu, Liting Zhang, Shuairan Zhang, Xiaoguo Li, Yu-Jun Wong, Xuan Liang, Yan Wang, Xiaofeng Wu, Wei Gou, Jiaojian Lv, et al.

    Introduction Patients with clinically significant portal hypertension (CSPH) are recommended to be treated with non-selective beta-blockers (ie, carvedilol) to prevent the first hepatic decompensation event by the renewing Baveno VII consensus. CSPH is defined by hepatic venous pressure gradient (HVPG)≥10 mm Hg; however, the HVPG measurement is not widely adopted due to its invasiveness. Liver stiffness (LS)≥25 kPa can be used as a surrogate of HVPG≥10 mm Hg to rule in CSPH with 90% of the positive predicting value in majority aetiologies of patients. A compelling argument is existing for using LS≥25 kPa to diagnose CSPH and then to initiate carvedilol in patients with compensated cirrhosis, and about 5%–6% of patients under this diagnosis criteria may not be benefited from carvedilol and are at risk of lower heart rate and mean arterial pressure. Randomised controlled trial on the use of carvedilol to prevent liver decompensation in CSPH diagnosed by LS remains to elucidate. Therefore, we aimed to investigate if compensated cirrhosis patients with LS≥25 kPa may benefit from carvedilol therapy. Methods and analysis This study is a randomised, double-blind, placebo-controlled, multicentre trial. We will randomly assign 446 adult compensated cirrhosis patients with LS≥25 kPa and without any previous decompensated event and without high-risk gastro-oesophageal varices. Patients are randomly divided into two groups, with 223 subjects in group A and 223 subjects in group B. Group A is a carvedilol intervention group, while group B is a placebo group. All patients in both groups will receive aetiology therapies and are followed up at an interval of 6 months. The 3-year incidences of decompensated events of cirrhosis-related and liver-related death are the primary outcome. The secondary outcomes include development of each complication of portal hypertension individually (ascites, variceal bleeding or overt hepatic encephalopathy), development of spontaneous bacterial peritonitis and other bacterial infections, development of new varices, growth of small varices to large varices, delta changes in LS and spleen stiffness, change in hepatic dysfunction assessed by Child-Pugh and model for end-stage liver disease score, change in platelet count, development of hepatocellular carcinoma, development of portal vein thrombosis and adverse events with a 3-year follow-up. A predefined interim analysis will be performed to ensure that the calculation is reasonable. Ethics and dissemination The study protocol has been approved by the ethics committees of the Sixth People’s Hospital of Shenyang (2023-05-003-01) and independent ethics committee for clinical research of Zhongda Hospital, affiliated to Southeast University (2023ZDSYLL433-P01). The results from this trial will be submitted for publication in peer-reviewed journals and will be presented at international conferences. Trial registration number ChiCTR2300073864.


  • Open Access

    Preliminary exploration of a multidisciplinary management model for cirrhotic portal hypertension

    by Changxiang Lai, Chuan Liu, Jitao Wang, Fang Wang

  • Open Access

    Shorter incubation period is associated with severe disease progression in patients with COVID-19

    by Changxiang Lai, Rentao Yu, Mingbo Wang, Wenjie Xian, Xin Zhao, Qiyuan Tang, Ruikun Chen, Xuan Zhou, Xuan Li, Zhiyu Li, et al.

    The diagnosed COVID-19 cases revealed that the incubation periods (IP) varied a lot among patients. However, few studies had emphasized on the different clinical features and prognosis of patients with different IP. A total of 330 patients with laboratory-confirmed COVID-19 were enrolled and classified into immediate onset group(IP10 days, L group, 75 cases) based on IP. The difference of clinical characteristics and prognosis of the two groups were compared. There were more patients with fever in I group than in L group(P = 0.003), and counts of all the total lymphocytes, total T lymphocytes, CD4 + and CD8 + T lymphocytes were significantly different between the two groups(all P < 0.01). Besides, patients in L group had more GGOs in CT scan than I group and there were more patients in I group receiving antibiotic treatment than in L group(P < 0.001). For disease aggravation, the median CT scores were comparable between the two groups, but individually, there were more patients with increased CT score during hospitalization in I group than in L group. The aggravation incidence of CT presentation was 21.1% in I group, significantly higher than L group(8.0%, P = 0.042). Multivariable COX models suggested that IP was the only independent factors for CT aggravation. Conclusively, patients with different IP were different in clinical symptoms, laboratory tests, and CT presentations. Shorter IP was associated with the aggravation of lung involvement in CT scan.


  • Open Access

    Initial Whole Genome Sequencing and Analysis of the Host Genetic Contribution to COVID-19 Severity and Susceptibility

    by Fang Wang, Shujia Huang, Rongsui Gao, Yuwen Zhou, Changxiang Lai, Zhichao Li, Wenjie Xian, Xiaobo Qian, Zhiyu Li, Yushan Huang, et al.

    The COVID-19 pandemic has accounted for more than five million infections and hundreds of thousand deaths worldwide in the past six months. The patients demonstrate a great diversity in clinical and laboratory manifestations and disease severity. Nonetheless, little is known about the host genetic contribution to the observed inter-individual phenotypic variability. Here, we report the first host genetic study in China by deeply sequencing and analyzing 332 COVID-19 patients categorized by varying levels of severity from the Shenzhen Third People’s Hospital. Upon a total of 22.2 million genetic variants, we conducted both single-variant and gene-based association tests among five severity groups including asymptomatic, mild, moderate, severe and critical ill patients after the correction of potential confounding factors. The most significant gene locus associated with severity is located in TMEM189-UBE2V1 involved in the IL-1 signaling pathway. The p.Val197Met missense variant that affects the stability of the TMPRSS2 protein displays a decreasing allele frequency among the severe patients compared to the mild and the general population. We also identified that the HLA-A*11:01, B*51:01 and C*14:02 alleles significantly predispose the worst outcome of the patients. This initial study of Chinese patients provides a comprehensive view of the genetic difference among the COVID-19 patient groups and highlighted genes and variants that may help guide targeted efforts in containing the outbreak. Limitations and advantages of the study were also reviewed to guide future international efforts on elucidating the genetic architecture of host-pathogen interaction for COVID-19 and other infectious and complex diseases.


  • Open Access

    Clinical characteristics of the recovered COVID-19 patients with re-detectable positive RNA test

    by Jianghong An, Xuejiao Liao, Tongyang Xiao, Shen Qian, Jing Yuan, Haocheng Ye, Furong Qi, Chengguang Shen, Yang Liu, Lifei Wang, et al.

    Summary: Background: It has been reported that several cases recovered from COVID-19 tested positive for SARS-CoV-2 after discharge (re-detectable positive, RP), however the clinical characteristics, significance and potential cause of RP patients remained elusive. Methods: A total of 262 COVID-19 patients were discharged from January 23 to February 25, 2020, and were enrolled for analysis of their clinical parameters. The RP and non-RP (NRP) patients were grouped according to the disease severity during their hospitalization period. The clinical characterization at re-admission to the hospital was analyzed. SARS-CoV-2 RNA and plasma antibody levels were detected using high-sensitive detection methods. Findings: Up to March 10, 2020, all of patients were followed up for at least 14 days, and 38/262 of RP patients (14.5%) were present. The RP patients were characterized by being less than 14-years old and having mild and moderate conditions as compared to NRP patients, while no severe patients became RP. Retrospectively, the RP patients displayed fewer symptoms, more sustained remission of CT imaging and earlier RNA negative-conversion but similar plasma antibody levels during their hospitalization period as compared to those NRP patients. When re-admitted to the hospital, these RP patients showed no obvious clinical symptoms or disease progression indicated by normal or improving CT imaging and inflammatory cytokine levels. All 21 close contacts of RP patients were tested negative for SARS-CoV-2 RNA, and no suspicious clinical symptoms were reported. However, 18/24 of RNA-negative samples detected by the commercial kit were tested to be positive for virus RNA using a hyper-sensitive method, suggesting the carrier status of virus possibly existed in patients recovered from COVID-19. Interpretation: Our results showed that young and mild COVID-19 patients seem to be RP patients after discharge, who show no obviously clinical symptoms and disease progression upon re-admission. More sensitive RNA detection methods are required to monitor these patients during follow-up. Our findings provide empirical information and evidence for the effective management of COVID-19 patients during their convalescent phase.


  • Open Access

    Effect of fibronectin on HBV infection in primary human fetal hepatocytes in vitro

    by Fang Wang, Xiaogang Zhang, Jing Zhang, Ling Hui, Yuming Wang, Xiaohong Wang

    This study was carried out to investigate the effect of fibronectin (FN) on primary cultured human fetal hepatocytes infected by hepatitis B virus (HBV) in vitro. Human fetal hepatocytes infected by HBV were cultured on culture dishes coated with FN in vitro. HBsAg and HBeAg in supernatants were detected by ELISA, HBcAg in nuclei by immunohistochemistry, HBV DNA by fluorescent quantitative PCR and covalently closed circular DNA (cccDNA) by nested PCR. The results were compared with cells cultured on dishes that were not coated with FN. Positivity for HBsAg and HBeAg in supernatants appeared from day 5 on the non-coated dishes, while positivity for HBsAg and HBeAg appeared from day 1 on the coated dishes. Positivity for HBcAg in the nuclei on the non‑coated dishes was displayed from day 2 with a positive rate of 15%, while positivity for HBcAg on the coated dishes was displayed from day 1 with a positive rate of >90%. HBV DNA in cells on the non-coated dishes was detected from day 4, while that on the coated dishes was detected from day 1. The non-coated dishes were positive for cccDNA from day 8, while the coated dishes were positive from day 2. FN coating is capable of accelerating HBV infection in primary cultured fetal hepatocytes in vitro, increasing the duration of HBV infection and the number of infected cells.


  • Open Access

    Action of progesterone on contractile activity of isolated gastric strips in rats

    by Fang Wang, Tian-Zhen Zheng, Wei Li, Song-Yi Qu, Di-Ying He

    AIM: To study the effect of progesterone on contractile activity of isolated gastric strips in rats. METHODS: Wistar rats were sacrificed to remove whole stomach. Then, the stomach was opened and the mucosal layer was removed. Parellel to either the circular or the longitudial fibers, muscle strips were cut from fundus, body, antrum and pylorus. Each muscle strip was suspended in a tissue chamber containing 5 mL Krebs solution. Then the motility of gastric strips in tissue chambers was simultaneously recorded. The preparations were subjected to 1 g load tension and washed with 5 ml Krebs solution every 20 min. After 1 h equilibration, progesterone or antagonists were added in the tissue chamber separately. The antagonists were added 3 min before using progesterone (50 µmol·L-1). RESULTS: Progesterone decreased the resting tension of fundus and body longitudinal muscle (LM) (P < 0.05). It inhibited the mean contractile amplitude of body and antrum LM and circular muscle (CM), and the motility index of pyloric CM (P < 0.05). The inhibition of progesterone on the mean contractile amplitude could be partially blocked by phentolamine in LM of the stomach body (the mean contractile amplitude of body LM decreased from -7.5 ± 5.5 to -5.2 ± 4.5 P < 0.01), and by phentolamine or indomethacin in CM of body (The inhibition of progesterone on the mean contractile amplitude of body CM decreased from -5.6 ± 3.0 to -3.6 ± 2.7 by phentolamine and from -5.6 ± 3.0 to -3.5 ± 2.5 by indomethacin, P < 0.01). Hexamethonium, propranolol and L-NNA (inhibitor of NO synthetase) didn’t affect the action of progesterone (P > 0.05). CONCLUSION: The study suggested that progesterone can inhibit the contractile activity of isolated gastric strips in rats and the mechanism seems to be a direct one except that the action on gastric body is mediated through prostaglandin and adrenergic α receptor partly.